Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Incyte
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral (ruxolitinib Tablet; Dexamethasone Tablet Or Injection), Intravenous (dexamethasone)
01
Overview
Ruxolitinib + dexamethasone is a combination therapy consisting of ruxolitinib, a selective Janus kinase 1 and 2 (JAK1/JAK2) inhibitor, and dexamethasone, a synthetic glucocorticoid. Ruxolitinib acts by inhibiting JAK1 and JAK2 kinases, thereby modulating cytokine signaling pathways involved in inflammation and hematopoiesis. Dexamethasone exerts potent anti-inflammatory and immunosuppressive effects primarily through binding to the glucocorticoid receptor. This combination is explored for its potential synergistic effects in diseases where both immune dysregulation and inflammation are prominent features, such as certain hematologic malignancies or inflammatory conditions[4][6]. In China, ruxolitinib is the only approved targeted therapy for myelofibrosis[2].
- Other names
- 芦可替尼联合地塞米松
02
Targets
Beyond the preview
Go deeper on ruxolitinib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + dexamethasone.